Navigation Links
Venture Fund with Key Focus on Alzheimer's Announces Investment in M3 Biotechnology and Its Drug Aimed at Regrowing Brain Cells
Date:2/17/2016

SEATTLE, Feb. 17, 2016 /PRNewswire/ -- Dolby Family Ventures, a venture fund managing a portfolio of investments specifically focused on companies targeting Alzheimer's and similar neurodegenerative disease, is backing Seattle-based M3 Biotechnology, Inc., according to M3 CEO Leen Kawas, Ph.D.

Photo - http://photos.prnewswire.com/prnh/20160216/333764

Announcement of the investment by Dolby Family Ventures, named for sound-system pioneer Ray Dolby who died three years ago with Alzheimer's, comes soon after Kawas announced completion of an oversubscribed Series A-Round. Dolby Family Ventures also invests in BioTechnologies with a neuro and brain-health focus, as well as more traditional early-stage technology companies including those in Virtual Reality, Home Automation / Connected Devices, IT Infrastructure, Security and 3D Printing.

The round was intended to be an $8 million raise but has been expanded to $10 million because of strong investor interest in M3, whose drug aimed at regrowing brain cells could put it at the leading edge of the emerging field of regenerative medicine.

The investment in M3 is among investments Dolby Family Ventures has made in what it describes as companies that "have the potential to accelerate a path to a cure" for Alzheimer's, its commitment to Alzheimer's Disease and brain-health therapeutics.

 "After losing my father, Ray Dolby, who battled Alzheimer's disease, my family has committed to pursuing a strategy that combines strategic investments made by Dolby Family Ventures, and philanthropic grants made by the Ray and Dagmar Dolby Family Fund, to help improve the lives of future Alzheimer's patients," said David Dolby.

The fund describes its involvements as taking "a long-term approach to our investments in our companies over their development cycle."

Kawas said the investment fits well with the pattern of investors who made their decisions to get financially involved "not merely focusing on the potential returns but also with a sense of responsibility to support the work addressing the biggest unmet medical need that is Alzheimer's and Parkinson's represent."

M3's leading-edge innovation is designed to be a pill that would address its target diseases in a non-invasive way as compared to Deep Brain Stimulation and other like technologies.

Kawas noted that success with the life-restoring potential of the company's initial drug, as well as related drugs in the pipeline, would quickly lead to domination in a multi-billion dollar regenerative-medicine market.

---------------------------------

For further information, contact:

Leen Kawas (Email) or Mike Flynn (Email) 206/240-5368, http://www.m3bio.com


'/>"/>
SOURCE M3 BioTechnology
Copyright©2016 PR Newswire.
All rights reserved


Related biology news :

1. NXT-ID Expands on Recent Announcement of Strategic Alliance With World Ventures
2. LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures
3. Valencell, Inc. Selected as Showcase Company at CED Tech Venture Conference 2014
4. Kalorama Report: Sizable Number of Acquisitions and Joint Ventures in Molecular Diagnostics
5. Marshall University to partner with international company in drug development venture
6. New venture aims to heal disrupted brain circuitry to treat mental illnesses
7. Ohr Pharmaceutical and CSHL joint venture to develop trodusquemine, related analogs
8. Drug development venture links translational research, business to launch new therapeutics
9. Focused Ion Beam Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2021
10. Connected Health Pioneer, Dr. Joe Kvedar, Publishes First Book, The Internet Of Healthy Things, Focusing On Technology-Enabled Health And Wellness, Trends And Business Opportunities
11. NXT-ID, Inc. to Exhibit Wocket Smart Wallet at Money20/20; Largest Global Event Focused on Payments and Financial Services Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2018)... ... , ... Right this minute, Frenchman Ben Lecomte is hard at work on his second ocean ... on a new challenge: going from Tokyo to San Francisco, churning his limbs eight hours ... support boat. As the first expedition of its kind, The Swim is far more than ...
(Date:8/31/2018)... and BOSTON, Mass. (PRWEB) , ... August 30, 2018 , ... ... Product and Customer Success. Jason has more than 20-years of telecommunications experience and over ... Sales at Appia Communications, which was acquired by CallTower in early 2018. , ...
(Date:8/31/2018)... and CARDIFF, Wales (PRWEB) , ... August 30, ... ... Agency. Martha Sanchez, senior scientist, IBM Research. Jacklyn Novak, infrared materials engineer, LightPath ... Katherine Johnson, the NASA mathematician who just celebrated her 100th birthday. Today, they ...
Breaking Biology News(10 mins):
(Date:9/22/2018)... Calif. and WESTMINSTER, Colo. (PRWEB) , ... ... ... Predicine and Flagship Biosciences are excited to announce a strategic venture. The ... cTA® digital pathology platform provides complimentary and comprehensive biomarker profiling to empower ...
(Date:9/15/2018)... ... ... recognized public accounting and consulting firm Cherry Bekaert LLP (“the Firm”) congratulates ... her appointment to Launch Tennessee’s Board of Directors. , Patrick has been ... Nashville practice in December 2017 . In this role, she oversees the execution of ...
(Date:9/12/2018)... Wash. (PRWEB) , ... September 11, 2018 , ... ... is proud to add flat sheet Forward Osmosis (FO) membranes from Fluid Technology ... FO membranes manufactured by FTS H2O are constructed from cellulose triacetate (CTA) material. ...
(Date:9/7/2018)... ... September 06, 2018 , ... ... commercialization, is releasing the agenda for its upcoming user conference. , This ... discussing the latest challenges, opportunities, and approaches to regulatory compliance and quality management. ...
Breaking Biology Technology: